LONDON (ShareCast) - (ShareCast News) - Purplebricks Group shares were a 'buy' in the Sunday Times' Inside the City column. Investing in this online estate agency might be a wild ride, with the shares trading for more than 40 times earnings, but some notable names are on the register since its IPO at the end of last year. The company is, the writer believes, reminiscent of Uber by disrupting an industry that has long been notorious for being expensive, inconvenient and leaving customers uncomfortable.
The company's business model is simple: it values homes, provides an online listing and connects buyers and sellers for a fraction of the price of a bricks-mortar-and-hair-gel estate agent without the a slick-talking salesman. Purplebricks, which launched in 2014, now lists around 3,000 homes monthly, making it one of the fourth largest agents in the country. The company and its shares will undoubtedly face some troubles ahead, including the slowing housing market, but offers long-term promise.

Shares of Associated British Foods are worth buying, said Questor in the Sunday Telegraph. Recently reliant on growth from its Primark clothing chain, AB Foods now looks likely to gain from the rally in US sugar prices after half a decade's decline. The group's sugar arm, which saw profits rot from above £430m to £43m in the previous two years, should benefit from bad weather hitting Brazil's harvest and cost cutting, though EU prices have yet to fully mirror the bounce in the US.

Meanwhile, though Primark endured a slower half-year as it launches in the USA, the grocery brands unit, which includes Ryvita, Jordans, Blue Dragon and Patak's, has been solid and improved profitability in the first half too. The conglomerate nature of the business meant these solid performances and even better from the ingredients business made up for a more difficult time for the agriculture arm. ABF is a powerful cash generator and healthy dividend payer. The shares are down by more than 10% this year but still are not lowly rated on a price-earnings basis.

Angle is a share for adventurous investors, said Midas in the Mail on Sunday. The medical technology company, which recently raised £10m, has developed a device that looks to improve cancer diagnosis and treatment by capturing and separating cancerous tumour cells from within a blood sample. Analysing cancer cells from the body presents several difficulties, especially with some cancers and when a patient has been in remission or if doctors want to check if it is metastasizing.

Angle's non-invasive liquid biopsy system, called Parsotix, is quite inexpensive and can allow an accurate diagnosis of the type of cancer. Parsortix has a CE mark for use as an in vitro diagnostic device in the EU but while it is available for research purposes in the US, it does not yet have FDA approval for clinical purposes. Research at the University of Southern California indicates the system can help to detect secondary cancers at an extremely early stage. Angle hopes to sell the equipment to hospitals for screening, detecting and monitoring cancer but in the meantime has been generating revenue and with wide profit margins by selling the kit to research organisations.


Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only and not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE